Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug not yet approved by the FDA. Always consult a qualified healthcare provider before starting any medication. If you are experiencing severe or worsening symptoms, seek medical evaluation.
Retatrutide / Safety Profile
RETATRUTIDE SIDE EFFECTS
What the Phase 2 data actually shows, how it compares to semaglutide and tirzepatide, and what we still don't know.
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC · Updated March 25, 2026
24.2%
mean body weight reduction at 48 weeks (12mg dose)
with side effects that deserve an honest look
Retatrutide is Eli Lilly's triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 2 trials, it produced up to 24.2% mean body weight reduction at 48 weeks — the largest weight loss ever recorded for any anti-obesity medication in clinical development.
That kind of result doesn't come without a side effect profile worth understanding. If you're researching retatrutide, you deserve an honest look at what the data shows — not a sales pitch that minimizes the downsides, and not a scare piece that strips out context.
Everything below comes from the published Phase 2 trial data (Jastreboff et al., NEJM 2023). Where we reference other GLP-1 medications, we cite the specific trials. Where we discuss topics like hair loss and facial changes that go beyond the published trial endpoints, we say so clearly.
GASTROINTESTINAL SIDE EFFECTS
GI effects are the most common side effects with retatrutide, as with all GLP-1 receptor agonists. They are dose-dependent, concentrated during titration, and generally improve over time. Here's what the Phase 2 data reported:
Nausea
25–45% by doseThe most commonly reported side effect. At lower doses (1–4mg), nausea affected roughly 25% of participants. At the highest dose (12mg), rates climbed to approximately 45%. Most episodes were rated mild to moderate. Nausea was worst during the first 4–8 weeks and during dose escalation — not at steady state.
Diarrhea
17–32% by doseThe second most common GI complaint. Similar dose-dependent pattern — lower doses in the 17% range, higher doses approaching 32%. Like nausea, this was most prevalent during titration and tended to resolve as the body adjusted to the medication.
Vomiting
9–18% by doseLess common than nausea but still significant, particularly at the 8mg and 12mg doses. Vomiting episodes were generally infrequent per patient — most who experienced it had only a few episodes during the titration phase, not ongoing vomiting throughout the trial.
Constipation
8–18% by doseGLP-1 agonists slow gastric motility — food stays in the stomach longer. This can manifest as either diarrhea or constipation depending on the individual. Adequate hydration and fiber intake help manage this.
Decreased Appetite
12–25% by doseThis is technically a "side effect" but also the primary mechanism of action for weight loss. Retatrutide reduces hunger signals at a neurological level. The question is degree — some patients find the appetite suppression manageable and welcome, others find it makes eating difficult. The goal is finding a dose where appetite is reduced but nutrition is still adequate.
The pattern matters: GI side effects with retatrutide are not constant. They spike during titration (when the dose is being increased) and diminish at steady state. This is consistent with the entire GLP-1 class. A slow, careful titration schedule significantly reduces both the severity and duration of these effects.
GI SIDE EFFECTS: RETATRUTIDE VS SEMAGLUTIDE VS TIRZEPATIDE
Comparing published trial data at the highest weight-loss doses for each medication. These are cross-trial comparisons (not head-to-head), so interpret directionally, not as exact equivalents.
| Side Effect | Retatrutide 12mg Phase 2, 48wk |
Semaglutide 2.4mg STEP 1, 68wk |
Tirzepatide 15mg SURMOUNT-1, 72wk |
|---|---|---|---|
| Nausea | ~45% | ~44% | ~31% |
| Diarrhea | ~32% | ~30% | ~23% |
| Vomiting | ~18% | ~24% | ~12% |
| Constipation | ~18% | ~24% | ~11% |
| Decreased Appetite | ~25% | ~20% | ~20% |
| Discontinuation (AEs) | ~6% | ~7% | ~6% |
What this tells us: Retatrutide's GI side effect profile at the 12mg dose is broadly comparable to high-dose semaglutide and somewhat higher than tirzepatide. This isn't surprising — all three drugs work on overlapping receptor systems. The clinical question isn't "which one has zero side effects" (none of them do) but rather which one provides the best efficacy-to-tolerability ratio for a given patient.
Sources: Jastreboff et al., NEJM 2023 (retatrutide); Wilding et al., NEJM 2021 (STEP 1 / semaglutide); Jastreboff et al., NEJM 2022 (SURMOUNT-1 / tirzepatide). Cross-trial comparison; not head-to-head data.
HEART RATE EFFECTS
In the Phase 2 trial, retatrutide was associated with a small, dose-dependent increase in resting heart rate. At lower doses (1–4mg), the mean increase was approximately 3–4 beats per minute. At the 12mg dose, the mean increase was approximately 6.7 bpm.
Context matters here. A resting heart rate increase of 3–7 bpm is consistent with what's seen across the entire GLP-1 receptor agonist class. Semaglutide produces a similar magnitude increase. Tirzepatide also raises heart rate modestly. This appears to be a class effect related to GLP-1 receptor activation, not something unique to retatrutide.
For perspective: the difference between a resting heart rate of 68 and 74 bpm is within normal physiological variation. Your heart rate fluctuates by more than that based on caffeine intake, sleep quality, stress, and hydration on any given day.
What the data shows
- Mean increase of ~3–4 bpm at 1–4mg doses
- Mean increase of ~6.7 bpm at the 12mg dose
- No clinically significant arrhythmias reported
- No cardiovascular serious adverse events attributed to the drug
Important caveats
- Phase 2 trial: ~338 participants, 48 weeks
- Not powered to detect rare cardiovascular events
- No long-term cardiovascular outcome data yet
- Patients with significant heart disease were excluded from the trial
The bigger picture: Semaglutide (Ozempic/Wegovy) recently demonstrated a 20% reduction in major adverse cardiovascular events in the SELECT trial — meaning the cardiovascular benefits of GLP-1 agonists may outweigh the small heart rate increase. Whether retatrutide will show similar cardiovascular benefit is unknown until its own outcome trials are completed.
SERIOUS ADVERSE EVENTS
In the Phase 2 trial, serious adverse events (SAEs) were infrequent and rates were similar between retatrutide groups and placebo. Here's what the data showed:
Pancreatitis
No cases of pancreatitis were reported in the Phase 2 trial. This is notable because pancreatitis has been a theoretical concern with GLP-1 agonists since the early days of exenatide. However, the Phase 2 sample size (~338 participants) is too small to definitively rule out a rare pancreatitis signal. Phase 3 trials with thousands of participants will provide more definitive data.
Discontinuation Rate
Approximately 6% of participants in the 12mg group discontinued due to adverse events. This is comparable to semaglutide (~7% in STEP 1) and tirzepatide (~6% in SURMOUNT-1). Most discontinuations were due to GI intolerance, not serious medical events. A 6% discontinuation rate means 94% of patients were able to continue the medication.
Gallbladder Events
Rapid weight loss from any cause increases the risk of gallstone formation. This is not unique to retatrutide — it's seen with bariatric surgery, very-low-calorie diets, and all GLP-1 medications. The Phase 2 trial did not flag gallbladder events as a significant concern, but this remains an area to monitor in Phase 3.
Thyroid / Medullary Thyroid Carcinoma
All GLP-1 receptor agonists carry a boxed warning for medullary thyroid carcinoma (MTC) based on rodent studies. No cases of thyroid cancer were reported in the retatrutide Phase 2 trial. The relevance of rodent thyroid findings to humans remains debated in the endocrinology literature — over 15 years of GLP-1 use in humans has not produced a clear signal. However, patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use GLP-1 medications.
Honest assessment: The Phase 2 safety data for retatrutide is reassuring but limited. A 48-week trial with ~338 participants can identify common side effects but cannot detect rare events that occur at rates of 1 in 1,000 or less. Phase 3 trials with larger populations and longer durations are where the full safety picture emerges. Anyone who claims retatrutide is definitively "safe" based on Phase 2 data alone is overstating the evidence.
HAIR LOSS
Hair loss was not reported as a significant adverse event in the Phase 2 retatrutide trial. But if you spend time in GLP-1 communities online, you'll see it mentioned constantly. So what's going on?
The answer is almost certainly telogen effluvium — a type of diffuse hair shedding triggered by physiological stress, including rapid weight loss and significant caloric deficit. This isn't a drug side effect. It's a weight-loss side effect.
When your body loses weight rapidly, it reallocates resources away from "non-essential" functions like hair growth. Hair follicles shift from the growth phase (anagen) to the resting phase (telogen) prematurely. Two to four months later, those hairs fall out. It looks alarming but is almost always temporary.
What actually helps
- Protein intake: This is the biggest lever. Aim for 0.7–1g of protein per pound of body weight daily. Hair is made of protein (keratin), and inadequate protein intake during caloric deficit accelerates shedding.
- Rate of weight loss: Slower, more controlled weight loss reduces the physiological stress signal. This is another argument for careful titration rather than jumping to the highest dose.
- Nutritional adequacy: Ensure sufficient iron, zinc, biotin, and vitamin D. Rapid weight loss on a nutrient-poor diet compounds the problem.
- Time: Telogen effluvium is self-limiting. Once weight stabilizes, hair typically regrows within 6–12 months.
Bottom line: If you lose 50+ pounds on retatrutide, you may experience some hair shedding. This is true regardless of how you lost the weight. The drug isn't attacking your hair follicles — the caloric deficit is. Protein and patience are the fix.
"OZEMPIC FACE" — FACIAL VOLUME LOSS
"Ozempic face" is the media term for facial volume loss that occurs with significant weight loss. It is not specific to Ozempic, semaglutide, or any particular medication. It happens with bariatric surgery. It happens with aggressive dieting. It will happen with retatrutide if you lose enough weight.
Here's the biology: your face stores fat in distinct compartments — the buccal fat pad, malar fat pad, and suborbital fat. When you lose substantial body fat, you also lose facial fat. This can make the face appear gaunt, aged, or hollow, particularly in patients over 40 who also have reduced collagen and skin elasticity.
The more weight you lose, the more pronounced this effect. Retatrutide, which produces more weight loss than any other medication in development, will likely produce more noticeable facial changes than lower-efficacy options. That's the honest trade-off.
Why it happens
- Significant total body fat loss includes facial fat loss
- More pronounced with larger weight loss (>15% body weight)
- Worse in older patients with less skin elasticity
- Not a drug-specific effect — any major weight loss causes it
What can be done
- Resistance training to preserve overall lean mass
- Adequate protein to support tissue maintenance
- Dermal fillers can restore volume if desired (cosmetic, not medical)
- Slower weight loss may reduce the degree of facial change
Real talk: If you need to lose 60+ pounds for health reasons, some facial volume loss is part of the trade-off. The metabolic benefits of moving from obese to healthy weight — reduced cardiovascular risk, improved insulin sensitivity, reduced joint stress, lower cancer risk — outweigh cosmetic facial changes. But you should know it's a possibility going in, not be surprised by it later.
MANAGING RETATRUTIDE SIDE EFFECTS
Most side effects from GLP-1 medications are manageable with the right strategies. The goal isn't to eliminate them entirely (some appetite suppression is the point) but to keep them from disrupting your life while the body adapts.
Slow Titration
The single most effective strategy. Starting at a low dose and increasing gradually gives GLP-1 receptors time to adapt. Rushing to a high dose dramatically increases GI side effects. Most clinics use 4–6 week titration intervals, adjusting based on tolerability rather than following a rigid calendar.
Smaller, More Frequent Meals
GLP-1 agonists slow gastric emptying. Eating a large meal on top of a stomach that's already processing slowly is a recipe for nausea. Smaller portions spread across 4–5 meals per day are typically better tolerated than 2–3 large meals.
Hydration & Electrolytes
Reduced food intake means reduced water and electrolyte intake from food. Many patients underestimate this. Aim for at least 80–100 oz of water daily. Consider an electrolyte supplement (sodium, potassium, magnesium) — especially if you're experiencing diarrhea, which depletes electrolytes faster.
Anti-Nausea Strategies
Ginger (tea, capsules, or chews) has evidence for nausea relief. Peppermint can help. Avoiding high-fat, greasy, or very spicy foods during titration reduces nausea triggers. If nausea is severe, your provider can prescribe ondansetron (Zofran) short-term during dose adjustments.
Protein Prioritization
When appetite is suppressed and you can't eat as much, what you eat matters more. Protein should be the priority at every meal — aim for 0.7–1g per pound of body weight daily. This preserves muscle mass, supports hair health, and maintains metabolic rate during weight loss.
Resistance Training
Not optional — essential. Strength training sends a "keep this muscle" signal to the body during caloric deficit. Patients who combine GLP-1 medications with consistent resistance training preserve significantly more lean mass than those who rely on medication alone. 2–4 sessions per week of compound movements.
WHAT WE DON'T KNOW YET
Being honest about the gaps in the data is more useful than pretending they don't exist. Retatrutide is still an investigational drug. Here's what the Phase 2 trial was not designed to tell us:
Long-Term Safety Beyond 48 Weeks
The Phase 2 trial ran for 48 weeks. Obesity medications are typically taken for years. We have no retatrutide data beyond one year. For context, semaglutide has 15+ years of post-market data. Tirzepatide has several years. Retatrutide has less than one year from a relatively small trial. Phase 3 trials are extending the duration, but multi-year real-world data won't exist for some time.
Rare Adverse Events
With ~338 participants, the Phase 2 trial can detect side effects that occur in roughly 1 in 100 patients. It cannot reliably detect events that occur in 1 in 1,000 or 1 in 10,000 patients. Those require Phase 3 trials (thousands of participants) and post-market surveillance (millions of patients). Some important drug safety signals have historically emerged only after widespread use.
Cancer Risk
No cancer signal was identified in the Phase 2 trial, but 48 weeks is far too short to assess cancer risk. The GLP-1 class carries a theoretical concern about medullary thyroid carcinoma based on rodent data, though this has not materialized in over 15 years of human GLP-1 use. Retatrutide's glucagon receptor agonism is a novel mechanism — we simply don't have enough data to make claims about long-term cancer risk in either direction.
Pregnancy & Fertility
There is no pregnancy data for retatrutide. GLP-1 medications are not recommended during pregnancy or while planning pregnancy. Retatrutide should be discontinued at least 2 months before conception (based on the drug's half-life). Notably, GLP-1 medications can improve fertility in women with PCOS and obesity, which means unplanned pregnancies can occur during treatment — a conversation that should happen before starting the medication.
Weight Regain After Stopping
The STEP 1 extension trial showed that patients who stopped semaglutide regained approximately two-thirds of lost weight within one year. We don't yet know what happens when patients stop retatrutide, but there's no biological reason to expect a different pattern. This isn't a failure of the medication — it's the biology of obesity. The disease doesn't resolve when you stop treating it, any more than blood pressure returns to normal when you stop antihypertensives.
RETATRUTIDE SIDE EFFECTS FAQ
Does retatrutide cause more nausea than Ozempic?
At comparable weight-loss doses, nausea rates are roughly similar. Retatrutide 12mg produced nausea in approximately 45% of participants; semaglutide 2.4mg (Wegovy) produced nausea in approximately 44% in the STEP 1 trial. Tirzepatide 15mg had lower nausea rates at approximately 31%. These are cross-trial comparisons, not head-to-head data, but they suggest retatrutide's nausea profile is in the same range as other high-efficacy GLP-1 medications. Slow titration reduces both incidence and severity.
Does retatrutide cause hair loss?
Hair loss was not formally reported as a significant adverse event in the Phase 2 trial. However, telogen effluvium (temporary hair shedding) is a well-documented consequence of rapid weight loss from any cause. If you lose a significant amount of weight on retatrutide, some hair shedding is possible 2–4 months into treatment. It's driven by caloric deficit and nutritional status, not the drug directly. Adequate protein intake (0.7–1g per pound of body weight) is the most important preventive measure.
Does retatrutide cause muscle loss?
All weight loss involves some lean mass loss — this is true whether the weight loss comes from medication, surgery, or diet alone. The lean-to-fat loss ratio with retatrutide is consistent with other GLP-1 medications. The mitigation strategy is the same: resistance training (2–4 times per week) and high protein intake. Patients who do both preserve significantly more muscle than those who lose weight passively. This is why we emphasize strength training as a non-negotiable companion to medical weight loss.
Does retatrutide cause heart problems?
No cardiovascular serious adverse events were attributed to retatrutide in the Phase 2 trial. There was a small, dose-dependent increase in resting heart rate (up to ~6.7 bpm at 12mg), which is a GLP-1 class effect. For broader context, semaglutide demonstrated a 20% reduction in major cardiovascular events in the SELECT trial, suggesting the GLP-1 class may actually be cardioprotective. Retatrutide-specific cardiovascular outcome data will come from Phase 3 trials. Patients with pre-existing heart conditions should discuss this with their provider.
Do retatrutide side effects go away?
For most patients, yes. GI side effects are most pronounced during the first 4–8 weeks and during each dose increase. As the body adapts, nausea, diarrhea, and vomiting typically diminish significantly. In the Phase 2 trial, the majority of GI events were rated mild to moderate and were transient. The most effective way to minimize side effects is slow, careful titration — increasing the dose only when the current dose is well-tolerated, not on a fixed schedule.
Is retatrutide safe long-term?
We don't have enough data to answer this definitively. The Phase 2 trial ran for 48 weeks with approximately 338 participants — enough to establish a short-term safety profile, not enough to identify rare events or long-term effects. Phase 3 trials are underway with larger populations and longer durations. The GLP-1 receptor agonist class has a strong safety record spanning 15+ years, which provides some baseline reassurance. But retatrutide's triple-agonist mechanism (GLP-1 + GIP + glucagon) is novel, and the glucagon component in particular deserves its own long-term evaluation. The honest answer is: we'll know more in 2–3 years.
References
- 1. Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." N Engl J Med. 2023;389(6):514-526.
- 2. Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." N Engl J Med. 2021;384(11):989-1002.
- 3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)." N Engl J Med. 2022;387(3):205-216.
- 4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." N Engl J Med. 2023;389(24):2221-2232.
- 5. Wilding JPH, Batterham RL, Davies M, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension)." Diabetes Obes Metab. 2022;24(8):1553-1564.
- 6. Malkova D, Polyviou T, Rizou E, et al. "Drug-induced hair loss and hair growth: incidence, management and avoidance." Drug Saf. 2021;44(5):499-516.
- 7. Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metab. 2018;27(4):740-756.
- 8. FDA. "Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers." 2005.
READY TO DISCUSS MEDICAL WEIGHT LOSS?
We'll walk through the options honestly — what's available now, what's coming, what makes sense for your situation, and what the realistic trade-offs are.
Explore Weight Loss Options